Subsense

Developer of non-surgical brain-computer interfaces using biocompatible nanoparticles. Developer of non-surgical brain-computer interfaces using biocompatible nanoparticles. This technology facilitates the recording and stimulation of neural activity, offering potential applications in treating neurological disorders, enhancing human-machine interaction, and improving diagnostic capabilities. The system's non-invasive nature ensures a safer and more accessible approach compared to traditional methods. The company operates in the Life Sciences > Neurology, High Tech > Brain Computer Interface sector. Founded in 2022 and headquartered in Covina, United States and has raised $27.0 million in Seed funding. Key investors include Golden Falcon Capital.